Approval · Notice of Compliance 33070 · 2024
TEVA-NARATRIPTAN: Notice of Compliance 33070
Issued April 17, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33070
- Date
- April 17, 2024
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Package Insert. Update to Labels
- Canadian reference product
- AMERGE (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-NARATRIPTAN | Not yet assigned | — |
Medicinal ingredients
- NARATRIPTAN HCL 1 MG per TAB
- NARATRIPTAN HCL 2.5 MG per TAB